Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIALYTE W DEXTROSE 4 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIALYTE W DEXTROSE 4 25 IN PLASTIC CONTAINER.
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER vs DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dialysis solution containing dextrose and electrolytes; dextrose provides osmotic gradient for ultrafiltration and caloric supplementation, while electrolytes maintain acid-base and electrolyte balance in peritoneal dialysis.
Intraperitoneal administration of dextrose creates an osmotic gradient that promotes ultrafiltration and removal of uremic toxins and excess fluid across the peritoneal membrane, while electrolytes in the solution correct imbalances.
Intravenous infusion, 500-2000 mL per day as maintenance fluid; rate adjusted based on clinical status, typically 1-2 mL/kg/hour in adults.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day, via continuous ambulatory peritoneal dialysis (CAPD).
None Documented
None Documented
Terminal half-life: 2.5–3.5 hours. Clinically, this allows for rapid clearance; accumulation may occur in renal impairment.
Not applicable (combination product); dextrose follows glucose kinetics (~1.5–2 h); electrolytes have no half-life.
Renal: >95% as unchanged drug and metabolites. Biliary/fecal: <5%.
Primarily renal; glucose is reabsorbed or metabolized; electrolytes follow renal handling. Not applicable as a drug; dialysate components are removed via peritoneal dialysis effluent.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution